Ronald Blue Trust, Inc. Affimed N.V. Transaction History

Ronald Blue Trust, Inc.

  • $7.98 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 18, 2024
BUY
$0.32 - $0.62 $107 - $207
335 New
335 $0
Q4 2022

Jan 17, 2023
BUY
$1.1 - $2.45 $3,339 - $7,438
3,036 Added 36.09%
11,448 $24,000
Q3 2022

Oct 21, 2022
BUY
$1.96 - $3.32 $4,629 - $7,841
2,362 Added 39.04%
8,412 $23,000
Q2 2022

Aug 09, 2022
BUY
$2.27 - $4.86 $13,733 - $29,403
6,050 New
6,050 $26,000

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email